Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

Trial Profile

Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Luminespib (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Based on the results of this trial, the recommended phase II dosage regimen is weekly cetuximab 250mg/m2 and luminespib 70mg/m2, according to the 51st ASCO abstract.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top